[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:brca1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","BRCA1 Gene",10,[8,16,22,28,35,41,48,54,60,66],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05687110","Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes",[12],"Phase 1","RECRUITING","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.808389Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06177171","Olaparib and ASTX727 in BRCA1\u002F2- and Homologous Recombination Deficient (HRD)-Mutated Tumors",[12],"2026-08-26T02:17:22.949982Z","2026-05-05T02:43:27.676733Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05694715","Combination Therapy in Cancers With Mutations in DNA Repair Genes",[12],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:28.876459Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT05700721","Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)",[32],"Phase 2","2026-08-26T02:19:26.493949Z","2026-05-05T02:43:26.981975Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06458712","Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies",[12],"2026-08-26T02:15:51.395565Z","2026-07-24T01:27:14.872137Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[45],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04890613","Study of CX-5461 in Patients With Solid Tumours and BRCA1\u002F2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation",[12],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:27.067991Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05841563","Clinical Trial of PM54 in Advanced Solid Tumors Patients.",[12],"2026-08-26T02:15:18.897219Z","2026-05-05T02:43:26.706220Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04494945","Identifying and Caring for Individuals With Inherited Cancer Syndrome",[],"2026-08-26T02:17:39.857430Z","2026-05-05T02:35:31.687767Z",{"nct_id":67,"title":68,"phases":69,"status":70,"updated_at":71,"content_modified":72},"NCT04550494","Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations",[32],"ACTIVE_NOT_RECRUITING","2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.385344Z"]